Academic Research
MEDICAL LITERATURE
The successful conclusion of the 2025 Chinese Medical Doctor Association Urological Surgeon Branch (CUDA) Annual Meeting
From June 13 to 15, 2025, the "2025 Chinese Medical Doctor Association Urologist Branch (CUDA) Annual Meeting" will be grandly held at the Zhuhai International Convention and Exhibition Center in Guangdong Province. The conference will attract top experts and scholars in the field of urology from home and abroad to gather together to discuss the latest developments and future directions of urological medicine, injecting new vitality into promoting the development of this field.
During the conference, many well-known experts conducted extensive exchanges and discussions on hot issues, academic frontiers, and difficult challenges in the field of urology. From new concepts in urological tumor treatment such as immunotherapy, targeted therapy, and the application of radioactive drugs, to important achievements in cutting-edge fields such as remote surgery and organ transplantation, and the latest advances in diagnostic technology, the content is comprehensive, bringing an academic feast to the participants.
Cheng Lai Pharmaceuticals cordially invited guests to visit its booth at this annual meeting, showcasing its innovative achievements in the field of urology, attracting the attention of many participants. The booth displayed innovative products, attracting urology experts and distributors from all over the world to stop and have in-depth exchanges on product characteristics and clinical applications. The staff enthusiastically explained the use and functional advantages of the products, highlighting high quality and high cost performance, becoming a highlight of the exhibition.
On the afternoon of June 14, the sub-venue was wonderfully presented. Professor Wei Wuran from West China Hospital of Sichuan University shared the "Innovative Application of Intelligent Laser Ablation System in Prostate Cancer and Urinary Tumors", focusing on its innovative application in the treatment of prostate cancer. The technology has the advantages of precision and minimally invasiveness, bringing new hope to patients and pointing out new directions for field research and clinical practice.
Follow Official Account
Chenglai Medicine(Beijing)Co.LTD
Room 217, 2nd Floor, Building 2, Airport Science and Technology Park, Shunyi District, Beijing
Copyright 2025 Chenglai Medicine(Beijing)Co.LTD